Orthocell’s Remplir Outperforms Standard Nerve Repair Techniques in New Study

The latest announcement is out from Orthocell Ltd ( (AU:OCC) ).

Orthocell Limited has announced compelling interim results from a study demonstrating the superiority of its Remplir product over traditional suture-only nerve repair techniques. The study, which supports the company’s US sales rollout, shows that Remplir leads to better nerve regeneration and earlier muscle function recovery, reducing adverse tissue reactions associated with sutures. These findings are expected to drive rapid market adoption and redefine the nerve repair market, with Orthocell targeting a total addressable market of over $3.5 billion across selected jurisdictions.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Limited is a regenerative medicine company based in Perth, Australia. The company focuses on developing and commercializing innovative products for the repair and regeneration of soft tissue injuries, particularly in the field of nerve repair. Its primary product, Remplir, is designed to enhance nerve regeneration and improve surgical outcomes.

Average Trading Volume: 1,326,887

Technical Sentiment Signal: Buy

Current Market Cap: A$293.2M

Learn more about OCC stock on TipRanks’ Stock Analysis page.